Clinical Trials in Hwasun, Jeollanam-do
8 recruiting
Showing 1–8 of 8 trials
Recruiting
Phase 1Phase 2
A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer
NSCLC
Regeneron Pharmaceuticals231 enrolled40 locationsNCT04077099
Recruiting
Phase 3
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
Relapsed Refractory Multiple Myeloma (RRMM)
Regeneron Pharmaceuticals410 enrolled159 locationsNCT05730036
Recruiting
Phase 2
Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma
Advanced or Metastatic Melanoma
Hanmi Pharmaceutical Company Limited45 enrolled10 locationsNCT07449754
Recruiting
Phase 3
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Non-small Cell Lung CancerAdvanced Non-Small Cell Lung CancerMetastatic Non Small Cell Lung Cancer+3 more
ArriVent BioPharma, Inc.480 enrolled23 locationsNCT07185997
Recruiting
Phase 1Phase 2
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Non-muscle Invasive Bladder Cancer With Carcinoma in SituSuperficial Bladder Cancer
enGene, Inc.350 enrolled100 locationsNCT04752722
Recruiting
Phase 2
A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer
Gastric CancerGastroesophageal Junction AdenocarcinomaGastric Adenocarcinoma
Toray Industries, Inc146 enrolled27 locationsNCT06038578
Recruiting
Not Applicable
Therapeutic Effect of Surgical Debulking of Metastatic Lymph Nodes in Cervical Cancer Stage IIICr
Cervical Cancer
CHA University240 enrolled26 locationsNCT05421650
Recruiting
Phase 3
Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma
Cholangiocarcinoma
TransThera Sciences (Nanjing), Inc.200 enrolled87 locationsNCT05948475